Drug Profile
Lanifibranor - Inventiva Pharma
Alternative Names: IVA-337Latest Information Update: 20 Mar 2024
Price :
$50
*
At a glance
- Originator Inventiva Pharma
- Class Anti-inflammatories; Antifibrotics; Antihyperglycaemics; Antineoplastics; Benzothiazoles; Butyric acids; Halogenated hydrocarbons; Hepatoprotectants; Indoles; Skin disorder therapies; Small molecules; Sulfones
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor delta agonists; Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Fibrosis; Non-alcoholic steatohepatitis
- Phase II Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Preclinical Liver cirrhosis
- No development reported Bladder cancer
- Discontinued Systemic scleroderma
Most Recent Events
- 18 Mar 2024 Interim PD, efficacy and adverse events data from a phase II LEGEND trial in Non-alcoholic fatty liver disease and Type 2 diabetes mellitus released by Inventiva Pharma
- 07 Mar 2024 Inventiva Pharma plans submission for potential accelerated approval to the US FDA and potential conditional approval to the EMA of lanifibranor for the treatment of Non-alcoholic steatohepatitis
- 07 Mar 2024 Inventiva lifts the voluntary pause on screening and randomization of its NATiV3 phase III clinical trial in Non-alcoholic steatohepatitis and Fibrosis